This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

15 Aug 2011

Mylan Launches Generic Prostate Drug

Mylan announced the launch of the generic version of Uroxatral for the treatment of benign prostatic hyperplasia.

Generic drugmaker Mylan Inc. announced last week that its subsidiary Mylan Pharmaceuticals Inc. has shipped Alfuzosin Hydrochloride Extended-release Tablets, 10 mg.


This product is the generic version of Uroxatral for the treatment of benign prostatic hyperplasia, or an enlarged prostate.


Uroxatral Tablets had U.S. sales of approximately $241 million for the 12 months ending June 30, 2011, according to IMS Health.


Currently, Mylan has 162 ANDAs pending FDA approval representing $94.4 billion in annual sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $25.5 billion in annual brand

Related News